Omeprazole 20mg Delayed Release Capsules
Indicated for Treatment of duodenal ulcers; Prevention of recurrence of duodenal ulcers; Treatment of gastric ulcers; Prevention of recurrence of gastric ulcers; In combination with appropriate antibiotics, eradication of Helicobacter pylori (H. Pylori) in peptic ulcers; Treatment of gastric and duodenal ulcers associated with NSAIDs; Prevention of gastric and duodenal ulcers associated with NSAIDs in patients at risk; Treatment of reflux esophagitis; Long-term control of cured gastroesophageal reflux disease; Treatment of symptomatic gastroesophageal reflux disease; Treatment of Zollinger-Elliso syndrome; Use in pediatrics; Children older than one year of age and weighing ≥10 kg; Treatment of reflux esophagitis; Symptomatic treatment of burning and acid regurgitation in gastroesophageal reflux disease; In combination with antibiotics for the treatment of duodenal ulcer caused by H. pylori.
Pharmaceutical form
Capsule
Concentration
20mg
Combination
N/A
Disclaimer: The content of this website is for pharmaceutical industry professionals interested in creating a strategic alliance with Wexford Laboratories. This page may contain information related to health, medical conditions, physical condition and its treatment. The information contained in this site is not to diagnose a health problem and is not a substitute for the advice provided by your doctor. Always consult a doctor when in doubt about a disease and its treatment. The products are subject to the applicable patent and registration laws of each country, and may not be allowed to be registered in some markets.
